Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease

Liver International

Volumn 34, Issue 7, 2014, Pages 1074-1083

  Kurek, Krzysztof ^a   Piotrowska, Dominika M ^a   Wiesiołek Kurek, Patrycja ^a   łukaszuk, Bartłomiej ^a   Chabowski, Adrian ^a   Górski, Jan ^a   Zendzian Piotrowska, Małgorzata ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Ceramide; Myriocin; Nonalcoholic fatty liver disease; Obesity; Sphingolipids

Indexed keywords

AMINOTRANSFERASE; CERAMIDE; GLUCOSE BLOOD LEVEL; INSULIN; MONOUNSATURATED FATTY ACID; THERMOZYMOCIDIN;

ANALYSIS OF VARIANCE; ANIMAL; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID METABOLISM; LIVER; MALE; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; RAT; SCINTILLATION COUNTING; WISTAR RAT;

ANALYSIS OF VARIANCE; ANIMALS; BIOSYNTHETIC PATHWAYS; BLOOD GLUCOSE; CERAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FATTY ACIDS, MONOUNSATURATED; INSULIN; LIPID METABOLISM; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RATS, WISTAR; SCINTILLATION COUNTING; TRANSAMINASES;

EID: 84904509368     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12331     Document Type: Article

References (36)

1. Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis 2012; 30: 158-62.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
3. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
4. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010; 53: 372-84.
5. Longato L, Tong M, Wands JR, de la Monte SM. High fat diet induced hepatic steatosis and insulin resistance: role of dysregulated ceramide metabolism. Hepatol Res 2012; 42: 412-27.
6. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-73.
7. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008; 28: 370-9.
8. Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J Biol Chem 2002; 277: 25847-50.
9. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-50.
10. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006; 45: 42-72.
11. Vanni E, Bugianesi E, Kotronen A, et al. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis 2010; 42: 320-30.
12. Trauner M, Arrese M, Wagner M. Fatty liver and lipotoxicity. Biochim Biophys Acta 2010; 1801: 299-310.
13. Hellemans K, Kerckhofs K, Hannaert JC, et al. Peroxisome proliferator-activated receptor alpha-retinoid X receptor agonists induce beta-cell protection against palmitate toxicity. FEBS J 2007; 274: 6094-105.
14. Anderson N, Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 2008; 60: 311-57.
15. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab 2012; 15: 574-84.
16. Petersen KF, Dufour S, Savage DB, et al. The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 2007; 104: 12587-94.
17. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-2.
18. Fujita T, Inoue K, Yamamoto S, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994; 47: 208-15.
19. Hanada K. Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta 2003; 1632: 16-30.
20. Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007; 5: 167-79.
21. Ussher JR, Koves TR, Cadete VJ, et al. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 2010; 59: 2453-64.
22. Yang G, Badeanlou L, Bielawski J, et al. Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2009; 297: E211-24.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911-7.
24. Min JK, Yoo HS, Lee EY, Lee WJ, Lee YM. Simultaneous quantitative analysis of sphingoid base 1-phosphates in biological samples by o-phthalaldehyde precolumn derivatization after dephosphorylation with alkaline phosphatase. Anal Biochem 2002; 303: 167-75.
25. Liu B, Hannun YA. Sphingomyelinase assay using radiolabeled substrate. Methods Enzymol 2000; 311: 164-7.
26. Nikolova-Karakashian M, Merrill AH Jr. Ceramidases. Methods Enzymol 2000; 311: 194-201.
27. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008; 28: 339-50.
28. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
29. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-61.
30. Takahashi Y, Soejima Y, Fukusato T. Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2012; 18: 2300-8.
31. Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Harasim E, Górski J. Chronic, in vivo, PPARalpha activation prevents lipid overload in rat liver induced by high fat feeding. Adv Med Sci 2009; 54: 59-65.
32. Chocian G, Chabowski A, Zendzian-Piotrowska M, et al. High fat diet induces ceramide and sphingomyelin formation in rat's liver nuclei. Mol Cell Biochem 2010; 340: 125-31.
33. Deevska GM, Rozenova KA, Giltiay NV, et al. Acid Sphingomyelinase Deficiency Prevents Diet-induced Hepatic Triacylglycerol Accumulation and Hyperglycemia in Mice. J Biol Chem 2009; 284: 8359-68.
34. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70.
35. Friedman J. Fat in all the wrong places. Nature 2002; 415: 268-9.
36. Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon 2012; 12: e6099.